Evidence map›Paper›PMID 39351862›Full record

ArticleNucleic acids research2024

Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil.

Susanta Chatterjee, Parisa Naeli, Okan Onar, Nicole Simms, Aitor Garzia, Angela Hackett, Kelsey Coyle, Patric Harris Snell, Tom McGirr, Tanvi Nitin Sawant and 13 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Quality control and signaling pathways at stalled ribosomes.Experimental & molecular medicine · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Susanta ChatterjeePatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Parisa NaeliPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Okan OnarPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Nicole SimmsDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.
Aitor GarziaLaboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Angela HackettPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Kelsey CoylePatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Patric Harris SnellPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Tom McGirrPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Tanvi Nitin SawantPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Kexin DangDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.
Zornitsa Vasileva StoichkovaDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.
Yumna AzamPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Mark P SaundersDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.
Michael BraunDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.ORCID 0000-0002-6666-4868
Tommy AlainChildren's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ONK1H 8L1, Canada.
Thomas TuschlLaboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.
Simon S McDadePatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.ORCID 0000-0002-3024-4773
Daniel B LongleyPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
Christos G GkogkasBiomedical Research Institute, Foundation for Research and Technology-Hellas, University Campus, 45110 Ioannina, Greece.
Colin AdrainPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.
John R P KnightDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9NT, UK.
Seyed Mehdi JafarnejadPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 9AE, UK.ORCID 0000-0002-5129-7081

Funding

Academy of Medical Sciences Springboard SBF007\100026Brainwaves Northern IrelandChristie CharityPatrick Johnston Research FellowshipQueen's University BelfastRoyal Society Research RGS\R1\221075Royal Society Research RGS\R2\222149Scientific and Technological Research Council of TurkeyUniversity of Manchester
6 · The paper itself

Abstract

Ribosome quality control (RQC) resolves collided ribosomes, thus preventing their cytotoxic effects. The chemotherapeutic agent 5-Fluorouracil (5FU) is best known for its misincorporation into DNA and inhibition of thymidylate synthase. However, while a major determinant of 5FU's anticancer activity is its misincorporation into RNAs, the mechanisms by which cancer cells overcome the RNA-dependent 5FU toxicity remain ill-defined. Here, we report a role for RQC in mitigating the cytotoxic effects of 5FU. We show that 5FU treatment results in rapid induction of the mTOR signalling pathway, enhanced rate of mRNA translation initiation, and increased ribosome collisions. Consistently, a defective RQC exacerbates the 5FU-induced cell death, which is mitigated by blocking mTOR pathway or mRNA translation initiation. Furthermore, 5FU treatment enhances the expression of the key RQC factors ZNF598 and GIGYF2 via an mTOR-dependent post-translational mechanism. This adaptation likely mitigates the cytotoxic consequences of increased ribosome collisions upon 5FU treatment.

Indexed as

FluorouracilRibosomesTOR Serine-Threonine KinasesAntimetabolites, AntineoplasticCell Line, TumorHumansPeptide Chain Initiation, TranslationalProtein BiosynthesisRNA, MessengerSignal TransductionAntimetabolites, AntineoplasticFluorouracilMTOR protein, humanRNA, MessengerTOR Serine-Threonine Kinases

Identifiers

PMID39351862
PMCPMC11551743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.